InspireMD’s Financial Growth in Q2 2025
MIAMI, InspireMD, Inc. (Nasdaq: NSPR), a leading developer of advanced medical devices, reported significant financial and operational results for the second quarter of 2025. Their CGuard Prime carotid stent system, designed for stroke prevention, continues to gain traction in the market.
Recent Business Highlights
This quarter has been a landmark period for InspireMD. The company achieved several major milestones:
- Achieved premarket application (PMA) approval from the U.S. FDA for the CGuard Prime carotid stent system.
- Launched the CGuard Prime carotid stent system commercially in the U.S. market.
- Secured $58 million in gross proceeds from an equity private placement and warrants exercise, fueling expansion strategies.
- Received CE Mark approval under the European Medical Device Regulation (MDR) for the CGuard Prime, preparing for a launch in the upcoming quarter.
- Strengthened the leadership team with the appointment of Mike Lawless as Chief Financial Officer.
- Appointed Raymond W. Cohen to the Board of Directors.
CEO Marvin Slosman’s Insights
CEO Marvin Slosman expressed enthusiasm about the company’s recent accomplishments, stating, “The past few months have been transformative for InspireMD. We have executed crucial milestones, validating our vision for the CGuard Prime carotid stent system. We are ready to harness our fully trained commercial team’s capabilities to reach our potential.”
He further emphasized, “The $58 million raised reflects strong investor confidence in our future. We are focused on establishing our technology as the standard in treating carotid artery disease and preventing strokes.”
Financial Performance Overview
In Q2 2025, InspireMD reported:
- A total revenue increase of $39,000 (2.3%), reaching $1,778,000 compared to $1,739,000 in Q2 2024.
- The gross profit for the quarter decreased by $18,000 (5.4%) to $313,000, down from $331,000 in Q2 2024.
- Total operating expenses increased to $13,332,000, a rise of 55.2%, reflecting expenses tied to U.S. sales force expansion, launch preparations, and facility costs.
- Net financial expense for the quarter was $132,000, shifting from financial income of $351,000 in Q2 2024 due to foreign exchange impacts.
- The net loss for the quarter was $13,151,000 or $0.26 per share, compared to a loss of $7,909,000 or $0.22 per share in 2024.
- Cash and cash equivalents along with marketable securities stood at $19,374,000 as of June 30, 2025, down from $34,637,000 by the end of 2024.
Looking Ahead
For the six months ended June 30, 2025, InspireMD reported a revenue uptick of $57,000 (1.8%) to $3,307,000 from $3,250,000 in 2024. The company anticipates growth opportunities through continued adoption of the CGuard technology, even amidst market challenges.
Conference Call and Webcast Details
To discuss the financial results and provide updates, InspireMD will host an investor conference call. Here are the details:
Date: Upcoming Tuesday call at 8:30 a.m. ET.
Domestic Call: 1-800-579-2543
International Call: 1-785-424-1789
Conference ID: IMD2Q25
Webcast: [Join Here](https://www.globenewswire.com/Tracker?data=Ryp6-R4QT5RXfsGrOaqlUrFurCO1uUBsvR5mNKOn6mILcr2D9ycA1uQVEGRksqSe_yZTLBe7xhzNo1EJnRFwPinxGVo6g28QOg1z9MbaNdc3BMXH2m6dj66kIec_FXvLw46QK3L7o8vLP-ym_4x7sNOX865_SUcp1dns7QpGJ4QREuudM48lMPhpJ9-nkInh8EWWprixrKJGndOos-ELUV8m_y5mtUp5JkL8N0rbrIjDHS2G5WKi7t4TK9TrF-azFFGbowuNz2z-Na0pJw_ZPaB2IThf43lDqqK17mJUc5z_0Xep6WBlaHNIBECucPer6p0h69wV9p4Z7b23iqyBcxP_Lm9wtK09V0GC7hlLOsZMScP_oFMqibTVihQZ-TF6yy1OIFzg7Iii7VxZuLioAwH2ZOoQyDpPyA6JcUvnjx1rlUsXn9pqnf2aghmbPOqhyWVr2TJgHUOi3KnEPW-L-Q== rel="nofollow" target="_blank")
About InspireMD, Inc.
InspireMD is dedicated to providing superior products utilizing its proprietary MicroNet™ mesh technology. This commitment aims to establish InspireMD products as the industry standard for carotid stenting, boasting remarkable acute results and sustaining long-term stroke-free outcomes. The company's shares are traded on Nasdaq under the ticker symbol NSPR.
Frequently Asked Questions
What major achievements did InspireMD report for Q2 2025?
InspireMD secured FDA approval for the CGuard Prime system, launched it commercially, and raised $58 million to support growth initiatives.
How did InspireMD's revenue change in Q2 2025?
Total revenue increased by $39,000, or 2.3%, reaching $1,778,000 compared to the previous year.
What can investors expect from the upcoming conference call?
The call will discuss financial results and corporate updates, with an interactive Q&A session following the presentation.
What is the focus of InspireMD's future growth?
InspireMD aims to position its CGuard technology as the new standard in carotid artery disease treatment, capitalizing on recent investment support.
Where can investors find more information about InspireMD?
Investors can visit InspireMD's official website or check their filings with the SEC for detailed information.
